HR5269

The RESULTS Act, HR5269, directly addresses the instability in Medicare reimbursement for clinical diagnostic laboratory tests. The bill amends Section 1834A(a) of the Social Security Act to improve the accuracy and feasibility of data collection for private payor-based fee schedules. This legislative action provides long-term stability for diagnostic testing companies by preventing the recurring cuts to reimbursement rates that have plagued the sector. The mechanism involves acquiring data for widely available non-advanced diagnostic laboratory tests from a qualifying comprehensive claims database of an independent national nonprofit entity, ensuring a more representative and stable basis for Medicare payments. Historically, the Protecting Access to Medicare Act (PAMA) of 2014 led to significant cuts in Medicare reimbursement for clinical laboratory tests, with initial cuts implemented in 2018 and subsequent reductions. These cuts created substantial financial pressure on diagnostic testing companies. For example, after PAMA's implementation, many smaller labs faced closure, and larger companies saw margin compression. This bill directly counters that trend by establishing a more robust and accurate data collection methodology, which will lead to more stable and potentially higher reimbursement rates than would otherwise occur under the current system. The bill's referral to the Committee on Energy and Commerce and the Committee on Ways and Means indicates it is moving through relevant legislative channels. Specific companies stand to gain significantly from this stability. LabCorp ($LH), Quest Diagnostics ($DGX), and Thermo Fisher Scientific ($TMO) are major providers of clinical diagnostic laboratory tests and will directly benefit from the predictable revenue streams and prevention of future reimbursement cuts. The bill's focus on improving data accuracy means that future rate adjustments will be based on more reliable market data, reducing the risk of arbitrary reductions. This regulatory relief translates directly into improved financial outlooks for these companies, as a significant portion of their revenue is tied to Medicare reimbursements. This bill's introduction by Rep. Hudson, a Republican, with 69 cosponsors, indicates broad bipartisan support, increasing its likelihood of passage. The referral to two key committees suggests a structured legislative path. If enacted, the stability provided by the RESULTS Act will allow these companies to better plan investments, research, and development, ultimately benefiting their bottom lines. The next step is committee consideration, which will determine the bill's progression.